WSS

• Notifications

  • focus

    • 1

      Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

    • 2

      Gilead might be held responsible for not developing a drug

    • 3

      BioAge raises $170M for combination therapy with Zepbound

    • 4

      Readout LOUD podcast: How biotech is using artificial intelligence

    • 5

      A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

    • 6

      Pfizer, Moderna say biotech, pharma drug development is a sprint

  Hepatitis C has a cure — but many Americans still lack access to it
• log on